Added to YB: 2026-06-04
Pitch date: 2026-06-02
ABVX [bullish]
ABIVAX Société Anonyme
+8.53%
current return
Author Info
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
EUR 5.0B
Pitch Price
EUR 65.65
Price Target
N/A
Dividend
N/A
EV/EBITDA
-18.08
P/E
-13.95
EV/Sales
929.14
Sector
Biotechnology
Category
special_situation
Obefazimod hit on cancer worry - $ABVX
ABVX: Obefazimod, most effective ulcerative colitis drug ever (40% placebo-adj remission), hit -20% after-hrs on data cut showing 7 cancer cases (5 types, non-clustered) in high-dose 50mg cohort (n=195) at wk44. Author thinks noise—prior long-term data showed no signal; recovering after-hrs. Even w/ black box, risk/benefit favorable given UC's own cancer risk.
Read full article (1 min)